A multimodal AI model may improve recurrence risk stratification in early breast cancer​A multimodal AI model may improve recurrence risk stratification in early breast cancer 

An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.